{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:27:22Z","timestamp":1750400842531},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study involved 63 patients with melanoma and 19 persons with vitiligo. Control group consisted up to 41 healthy volunteers. Mushroom tyrosinase and synthetic melanin were used as the antigens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>ELISA test showed significantly (p\u2009&lt;\u20090.0000004 and p\u2009&lt;\u20090.04) lower levels of IgM anti-tyrosinase autoantibodies, in melanoma and vitiligo patients respectively, compared to controls.<\/jats:p>\n            <jats:p>Although there was no significant difference between the levels of IgA anti-melanin autoantibodies in melanoma or vitiligo patients in comparison with controls, the enhanced concentrations of anti-melanin IgA autoantibodies were preferentially found in melanoma patients with metastatic disease. Significantly high percentage in the Fc alphaRI (CD89) positive cells was determined in melanoma patients (p\u2009&lt;\u20090.002 and p\u2009&lt;\u20090.008) in comparison to that found in healthy people or in patients with vitiligo, in the already mentioned order, pointing that IgA dependent cellular cytotoxicity is not important for the immune action against melanoma, even more that it is included in some immune suppression.<\/jats:p>\n            <jats:p>Levels of IgG autoantibodies to mentioned antigens in melanoma patients although low were not significantly lower from controls. These findings analyzed together with the statistically significant low percentage of FcgammaRIII, (CD16) positive immunocompetent cells (p\u2009&lt;\u20090.0007 and p\u2009&lt;\u20090.003), which was found in patients with melanoma compared with healthy or vitiligo people respectively, and statistically significant low percentage of (CD16\u2009+\u2009CD56+) natural killer (NK) cells (p\u2009&lt;\u20090.005) found in melanoma patients in comparison to healthy controls pointed to the low probability for anti-melanoma IgG mediated, antibody mediated cellular cytotoxicity, (ADCC) and NK cytotoxicity. Moreover the ratio of the percentages of granulocytes and percentage of lymphocytes was statistically higher in patients with melanoma in relation to healthy people as well as to people with vitiligo (p\u2009&lt;\u20090.0007 and p\u2009&lt;\u20090.05 respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Autoantibodies to tyrosinase and to melanin which are found even in healthy people, point that consummation of edible mushrooms that carry the antigen tyrosinase and melanin, could influence the humoral anti-melanoma immune response.<\/jats:p>\n            <jats:p>Levels of different immunoglobulin classes of anti-melanin and anti-tyrosinase antibodies varied depending on the presence and the stage of studied diseases. Besides, the statistically enhanced ratio of the percentages of granulocytes and percentage of lymphocytes, together with statistically decreased percentage of NK cells is found in analyzed melanoma patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6882-12-109","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T16:03:50Z","timestamp":1343318630000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo"],"prefix":"10.1186","volume":"12","author":[{"given":"Marija","family":"\u0110or\u0111i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana Z","family":"Mati\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Filipovi\u0107-Lje\u0161kovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radan","family":"D\u017eodi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miomir","family":"\u0160a\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Eri\u0107-Nikoli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vuleti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branka","family":"Kolund\u017eija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Damjanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na\u0111a","family":"Grozdani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sr\u0111an","family":"Nikoli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janko","family":"Pralica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Dobrosavljevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanvila","family":"Ra\u0161kovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sla\u0111ana","family":"Andrejevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zorica","family":"Jurani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"1072_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","volume":"19","author":"LV Kalialis","year":"2009","unstructured":"Kalialis LV, Drzewiecki KT, Klyver H: Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009, 19: 275-282. 10.1097\/CMR.0b013e32832eabd5.","journal-title":"Melanoma Res"},{"issue":"Suppl 6","key":"1072_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/annonc\/mdp253","volume":"20","author":"D Schadendorf","year":"2009","unstructured":"Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P: Immunotherapy of distant metastatic disease. Ann Oncol. 2009, 20 (Suppl 6): 41-50.","journal-title":"Ann Oncol"},{"key":"1072_CR3","volume-title":"Int J Cancer","author":"R Carretero","year":"2011","unstructured":"Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T: Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2011, 10.1002\/ijc.26471."},{"key":"1072_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.yasu.2011.04.003","volume":"45","author":"S Turcotte","year":"2011","unstructured":"Turcotte S, Rosenberg SA: Immunotherapy for metastatic solid cancers. Adv Surg. 2011, 45: 341-360. 10.1016\/j.yasu.2011.04.003.","journal-title":"Adv Surg"},{"key":"1072_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1440-0960.2009.00556.x","volume":"50","author":"DL Damian","year":"2009","unstructured":"Damian DL, Shannon KF, Saw RP, Thompson JF: Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol. 2009, 50: 266-271. 10.1111\/j.1440-0960.2009.00556.x.","journal-title":"Australas J Dermatol"},{"key":"1072_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1758834011415308","volume":"3","author":"RN Amaria","year":"2011","unstructured":"Amaria RN, Lewis KD, Gonzalez R: Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol. 2011, 3: 245-251. 10.1177\/1758834011415308.","journal-title":"Ther Adv Med Oncol"},{"key":"1072_CR7","doi-asserted-by":"publisher","first-page":"16723","DOI":"10.1073\/pnas.1110814108","volume":"108","author":"J Yuan","year":"2011","unstructured":"Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 2011, 108: 16723-16728. 10.1073\/pnas.1110814108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1072_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1158\/1055-9965.EPI-09-0278","volume":"18","author":"CM Vajdic","year":"2009","unstructured":"Vajdic CM, van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, Chapman JR, Amin J, McDonald SP, Grulich AE: Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev. 2009, 18: 2297-2303. 10.1158\/1055-9965.EPI-09-0278.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1072_CR9","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011, 17: 4550-4557. 10.1158\/1078-0432.CCR-11-0116.","journal-title":"Clin Cancer Res"},{"key":"1072_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrclinonc.2011.119","volume":"8","author":"VK Sondak","year":"2011","unstructured":"Sondak VK, Flaherty LE: Targeted therapies: Improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol. 2011, 8: 513-515. 10.1038\/nrclinonc.2011.119.","journal-title":"Nat Rev Clin Oncol"},{"key":"1072_CR11","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","volume":"47","author":"AM Eggermont","year":"2011","unstructured":"Eggermont AM, Robert C: New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011, 47: 2150-2157. 10.1016\/j.ejca.2011.06.052.","journal-title":"Eur J Cancer"},{"key":"1072_CR12","volume-title":"Cancer Immunol Immunother","author":"AM Van Nuffel","year":"2011","unstructured":"Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A: Intravenous and intradermal TriMix-dendritic cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother. 2011, 10.1007\/s00262-011-1176-2."},{"key":"1072_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1346-8138.2010.00877.x","volume":"37","author":"N Nishitani","year":"2010","unstructured":"Nishitani N, Bito T, Ikeda T, Tokura Y, Nishigori C: Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo. J Dermatol. 2010, 37: 770-772. 10.1111\/j.1346-8138.2010.00877.x.","journal-title":"J Dermatol"},{"key":"1072_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18632\/oncotarget.323","volume":"2","author":"KT Byrne","year":"2011","unstructured":"Byrne KT, Turk MJ: New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011, 2: 684-694.","journal-title":"Oncotarget"},{"key":"1072_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CMR.0b013e32834b58fa","volume":"21","author":"L Ridolfi","year":"2011","unstructured":"Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R: Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res. 2011, 21: 524-529. 10.1097\/CMR.0b013e32834b58fa.","journal-title":"Melanoma Res"},{"key":"1072_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1479-5876-8-52","volume":"8","author":"L Fiammenghi","year":"2010","unstructured":"Fiammenghi L, Ancarani V, Rosales T, Knutson JR, Petrini M, Granato AM, Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P: FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy. J Transl Med. 2010, 8: 52-10.1186\/1479-5876-8-52.","journal-title":"J Transl Med"},{"key":"1072_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1755-148X.2010.00736.x","volume":"23","author":"N Nakai","year":"2010","unstructured":"Nakai N, Hartmann G, Kishimoto S, Katoh N: Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res. 2010, 23: 607-619. 10.1111\/j.1755-148X.2010.00736.x.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1072_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/cbr.2007.0432","volume":"23","author":"PM Schiltz","year":"2008","unstructured":"Schiltz PM, Dillman RO, Korse CM, Cubellis JM, Lee GJ, De Gast GC: Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm. 2008, 23: 214-221. 10.1089\/cbr.2007.0432.","journal-title":"Cancer Biother Radiopharm"},{"key":"1072_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12185-009-0383-5","volume":"90","author":"ZD Jurani\u0107","year":"2009","unstructured":"Jurani\u0107 ZD, Besu I, Jeli\u0107 S, Koni\u0107-Risti\u0107 A, Matkovi\u0107 S, Jankovi\u0107 L, Gavrilovi\u0107 D, Radojci\u0107 B, Mini\u0107 I: Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. Int J Hematol. 2009, 90: 212-216. 10.1007\/s12185-009-0383-5.","journal-title":"Int J Hematol"},{"key":"1072_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2172-10-32","volume":"10","author":"A Konic-Ristic","year":"2009","unstructured":"Konic-Ristic A, Dodig D, Krstic R, Jelic S, Stankovic I, Ninkovic A, Radic J, Besu I, Bonaci-Nikolic B, Jojic N, Djordjevic M, Popovic D, Juranic Z: Different levels of humoral immunoreactivity to different wheat cultivars gliadin are present in patients with celiac disease and in patients with multiple myeloma. BMC Immunol. 2009, 10: 32-10.1186\/1471-2172-10-32.","journal-title":"BMC Immunol"},{"key":"1072_CR21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1601-0825.2009.01595.x","volume":"15","author":"I Besu","year":"2009","unstructured":"Besu I, Jankovic L, Magdu IU, Konic-Ristic A, Raskovic S, Juranic Z: Humoral immunity to cow's milk proteins and gliadin within the etiology of recurrent aphthous ulcers?. Oral Dis. 2009, 15: 560-564. 10.1111\/j.1601-0825.2009.01595.x.","journal-title":"Oral Dis"},{"key":"1072_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/B978-044482824-8\/50032-4","volume-title":"The Decade of Autoimmunity","author":"O Merimsky","year":"1999","unstructured":"Merimsky O, Shoenfeld Y, Fishman P: A focus on anti-tyrosinase antibodies in melanoma and vitiligo. The Decade of Autoimmunity. 1999, Elsevier Science B.V, Amsterdam, 261-267."},{"key":"1072_CR23","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E","volume":"79","author":"P Fishman","year":"1997","unstructured":"Fishman P, Merimski O, Baharav E, Shoenfeld Y: Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer. 1997, 79: 1461-1464. 10.1002\/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO;2-E.","journal-title":"Cancer"},{"key":"1072_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1365-2249.1996.d01-727.x","volume":"105","author":"E Baharav","year":"1996","unstructured":"Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G, Youinou P, Fishman P: Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol. 1996, 105: 84-88. 10.1046\/j.1365-2249.1996.d01-727.x.","journal-title":"Clin Exp Immunol"},{"key":"1072_CR25","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1158\/1078-0432.CCR-08-2376","volume":"15","author":"E Revskaya","year":"2009","unstructured":"Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, Nosanchuk JD, Casadevall A, Dadachova E: Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res. 2009, 15: 2373-2379. 10.1158\/1078-0432.CCR-08-2376.","journal-title":"Clin Cancer Res"},{"key":"1072_CR26","first-page":"305","volume":"50","author":"ZD Juranic","year":"2003","unstructured":"Juranic ZD, Stanojevic-Bakic N, Zizak Z, Babovic N, Radovic-Kovacevic V, Stanojkovic T, Dzodic R: Antimelanoma immunity in vitiligo and melanoma patients. Neoplasma. 2003, 50: 305-309.","journal-title":"Neoplasma"},{"key":"1072_CR27","doi-asserted-by":"publisher","first-page":"316314","DOI":"10.1155\/2011\/316314","volume":"2011","author":"SG Holtan","year":"2011","unstructured":"Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN: Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol. 2011, 2011: 316314-","journal-title":"Clin Dev Immunol"},{"key":"1072_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/0190-9622(93)70103-Z","volume":"28","author":"G Cartei","year":"1993","unstructured":"Cartei G, Sala PG, Sanzari M, Ceschia V, Clocchiatti L, Sibau A, Don\u00e0 S, Giovannoni M, Vigevani E: Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol. 1993, 28: 738-744. 10.1016\/0190-9622(93)70103-Z.","journal-title":"J Am Acad Dermatol"},{"key":"1072_CR29","volume-title":"J Nutr Biochem","author":"T P\u00e9rez-Berezo","year":"2011","unstructured":"P\u00e9rez-Berezo T, Franch A, Castellote C, Castell M, P\u00e9rez-Cano FJ: Mechanisms involved in down-regulation of intestinal IgA in rats by high cocoa intake. J Nutr Biochem. 2011, 10.1016\/j.jnutbio.2011.04.008"},{"key":"1072_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jnutbio.2007.07.002","volume":"19","author":"E Ramiro-Puig","year":"2008","unstructured":"Ramiro-Puig E, P\u00e9rez-Cano FJ, Ramos-Romero S, P\u00e9rez-Berezo T, Castellote C, Permanyer J, Franch A, Izquierdo-Pulido M, Castell M: Intestinal immune system of young rats influenced by cocoa-enriched diet. J Nutr Biochem. 2008, 19: 555-565. 10.1016\/j.jnutbio.2007.07.002.","journal-title":"J Nutr Biochem"},{"key":"1072_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.vetimm.2011.08.019","volume":"144","author":"JS Park","year":"2011","unstructured":"Park JS, Mathison BD, Hayek MG, Massimino S, Reinhart GA, Chew BP: Astaxanthin stimulates cell-mediated and humoral immune responses in cats. Vet Immunol Immunopathol. 2011, 144: 455-461. 10.1016\/j.vetimm.2011.08.019.","journal-title":"Vet Immunol Immunopathol"},{"key":"1072_CR32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.437","volume":"3","author":"M Schlaak","year":"2012","unstructured":"Schlaak M, Schmidt P, Bangard C, Kurschat P, Mauch C, Abken H: Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 2012, 3: 22-30.","journal-title":"Oncotarget"},{"key":"1072_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1475-2891-10-89","volume":"10","author":"T Mueller","year":"2011","unstructured":"Mueller T, Voigt W: Fermented wheat germ extract - nutritional supplement or anticancer drug?. Nutr J. 2011, 10: 89-10.1186\/1475-2891-10-89.","journal-title":"Nutr J"},{"key":"1072_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00403-010-1094-8","volume":"303","author":"K Sato","year":"2011","unstructured":"Sato K, Takahashi H, Toriyama M: Depigmenting mechanism of NSAIDs on B16F1 melanoma cells. Arch Dermatol Res. 2011, 303: 171-180. 10.1007\/s00403-010-1094-8.","journal-title":"Arch Dermatol Res"},{"key":"1072_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.phrs.2005.11.003","volume":"53","author":"AM Sadowska","year":"2006","unstructured":"Sadowska AM, Manuel-y-Keenoy B, Vertongen T, Schippers G, Radomska-Lesniewska D, Heytens E, De Backer WA: Effect of N-acetylcysteine on neutrophil activation markers in healthy volunteers: in vivo and in vitro study. Pharmacol Res. 2006, 53: 216-225. 10.1016\/j.phrs.2005.11.003.","journal-title":"Pharmacol Res"},{"key":"1072_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0022-1759(91)90327-C","volume":"145","author":"M Ohno","year":"1991","unstructured":"Ohno M, Abe T: Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J Immunol Methods. 1991, 145: 199-203. 10.1016\/0022-1759(91)90327-C.","journal-title":"J Immunol Methods"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-12-109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6882-12-109\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6882-12-109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:49:00Z","timestamp":1630525740000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/1472-6882-12-109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1186\/1472-6882-12-109","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]},"assertion":[{"value":"19 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"109"}}